Wintermute Biomedical is an antimicrobials-focused pharmaceutical company located in Melbourne, Australia and Missoula, Montana. We have developed a novel platform for harnessing the antimicrobial activity of fatty acids. with a focus on developing a next-generation treatment for Shingles. Our lead product GS-1 will soon be entering clinical trials. Our vision is to make GS-1 available for the millions of people that fall victim to Shingles each year.